Skip to main content
Cedar Bluff
Marion 276-521-4446
Cedar Bluff 276-991-3171
Bristol, TN 423-546-4536

AdaptDx by Maculogix

Digital Eye Exam Technology Detects AMD Even Earlier

There are a variety of standard techniques that your eye doctor performs for detecting the signs of age-related macular degeneration (AMD). For example, the following tests may be done during your comprehensive eye exam:

  • Inspecting for the presence of drusen, fatty proteins that appear as yellow deposits under the retina. Drusen are a good indicator of macular degeneration.
  • Performing an OCT scan or doing a fluorescein angiogram to look for abnormal blood vessels in your eye.
  • Testing visual acuity by having you look at an Amsler grid; if any lines of the grid appear wavy or broken, it may be a sign of the eye disease.

The Science Behind AdaptDx:

adaptdxDark adaptation function, the recovery of vision when going from daylight to darkness, is the only biomarker of age-related macular degeneration (AMD).  AdaptDx provides a practical and objective way to measure dark adaptation with a test that can be completed in just a few minutes.

AdaptDx is not only much faster than older methods, but also more sensitive and specific. In clinical studies involving more than 1,000 patients, AdaptDx has proven to be 90% sensitive and 90% specific for the presence of AMD. The clinical studies were conducted at renowned research centers such as Harvard University, Duke University, the National Eye Institute, and the University of Alabama at Birmingham. Gregory Jackson, PhD, Co-founder and Chief Technology Officer of Maculogix, is the principal inventor of AdaptDx and one of the world’s leading experts on AM and dark adaptation.

AdaptDx is supported by more than twenty patents and has received FDA 510(k) clearance and a CE mark. It is also cleared for use in Canada.

Why Test for AMD?

According to recent studies, at least 25% of AMD is undiagnosed by primary eyecare professionals in a dilated fundus examination. We can do better.

Leading-edge ophthalmologists and optometrists in eight countries on three continents around the world use the AdaptDx. By using the AdaptDx, they have more than doubled their diagnosis of AMD patients who otherwise might not have been identified until vision loss occurred.

Early detection and monitoring can prevent unnecessary vision loss by facilitating interventions at the earliest possible stages. For example, in NIH-sponsored clinical trials, intervention with vitamin therapy has been proven as effective in managing dry AMD as anti-VEGF therapy is in slowing the progression of AMD.

AdaptDX aids early diagnosis of AMD

Even with all of the cutting-edge optometric equipment available, statistics report that 70% of patients are unaware that they have a serious eye disease until they suffer vision loss that may be permanent. This state of affairs underscores the need for more sophisticated digital eye exam technologies, such as AdaptDX by MacuLogix.

 Dark adaptation – expressed by patients as having trouble seeing at night – can be a very reliable indicator of macular degeneration. In fact, dramatically impaired night vision can appear from the very beginning of AMD, and it increases regularly as the eye disease develops. It is often a clear sign of AMD that presents up to three years before drusen become visible.

AdaptDX is the first device designed to test a patient’s dark adaptation quickly and conveniently within the comfort of your local eye care center. In the past, dark adaptation testing was a very long process that required about one hour of evaluation per eye!

Administering the AdaptDx Test

The test is non-invasive. It’s conducted in a darkened room with the patient’s chin and forehead resting on comfortable supports similar to those on other eye care instruments. With a 92% concordance of dark adaptation status between eyes, the AdaptDx can be used unilaterally for screening and monitoring.

Measurement starts by exposing the test eye to a mild flash (less intense than a normal camera flash) to pre‐condition the retina to a standard photobleached state. The patient is then asked to focus on a fixation light and indicate with a hand-held response button when a stimulus light appears. Stimulus lights are presented at a fixed location using a pattern of generally decreasing intensities to determine visual sensitivity recovery.

Most patients report the experience is similar to visual field testing for glaucoma and it takes about the same amount of time.

Please visit our Macular Degeneration page to learn more about AMD.

AdaptDX can help prevent vision loss

By including AdaptDX as an essential part of your digital eye exam, your eye doctor is offering a practical way to take immediate and effective action towards delaying or preventing vision loss from macular degeneration.